Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1-6 Infection and Compensated Cirrhosis: The Expedition-8 Study

被引：0

作者：

Brown, Robert S., Jr. ^{[1
]}

Hezode, Christophe ^{[2
]}

Wang, Stanley ^{[3
]}

Buti, Maria ^{[4
,5
]}

Chuang, Wan-Long ^{[6
,7
]}

Aguilar, Humberto I. ^{[8
]}

Horvath, Gabor ^{[9
]}

Rosado-Carrion, Barbara ^{[10
]}

Rodriguez-Perez, Federico ^{[11
,12
]}

Cohen, Eric ^{[3
]}

Hui, Yiran B. ^{[3
]}

Schnell, Gretja ^{[3
]}

Lin, Chih-Wei ^{[3
]}

Rodrigues, Lino, Jr. ^{[3
]}

Trinh, Roger ^{[3
]}

Mensa, Federico J. ^{[3
]}

Felizarta, Franco

机构：

[1] New York Presbyterian Hosp, Cornell Med Coll, Dept Med, Ctr Liver Desease & Transplantat, Nyc, NY USA

[2] Univ Paris Est, Hop Henri Mondor, Dept Hepatol, Paris, France

[3] Abbvie Inc, N Chicago, IL USA

[4] Hosp Univ Vall dHebron, Barcelona, Spain

[5] Vall DHebron Univ Hosp, Liver Unit, Barcelona, Spain

[6] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan

[7] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatitis Ctr, Kaohsiung, Taiwan

[8] Louisiana Res Ctr, Shreveport, LA USA

[9] Hepatol Ctr Buda, Budapest, Hungary

[10] Ghgcpr Res Inst, Ponce, PR USA

[11] Ghwc, San Juan, PR USA

[12] Gastroenterol Sect, San Juan, PR USA

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

715A

引用

页码：425A / 426A

页数：2

共 50 条

[21] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang
Chung-Feng Huang
Hsing-Tao Kuo
Ching-Chu Lo
Chien-Wei Huang
Lee-Won Chong
Pin-Nan Cheng
Ming-Lun Yeh
Cheng-Yuan Peng
Chien-Yu Cheng
Jee-Fu Huang
Ming-Jong Bair
Chih-Lang Lin
Chi-Chieh Yang
Szu-Jen Wang
Tsai-Yuan Hsieh
Tzong-Hsi Lee
Pei-Lun Lee
Wen-Chih Wu
Chih-Lin Lin
Wei-Wen Su
Sheng-Shun Yang
Chia-Chi Wang
Jui-Ting Hu
Lein-Ray Mo
Chun-Ting Chen
Yi-Hsiang Huang
Chun-Chao Chang
Chia-Sheng Huang
Guei-Ying Chen
Chien-Neng Kao
Chi-Ming Tai
Chun-Jen Liu
Mei-Hsuan Lee
Pei-Chien Tsai
Chia-Yen Dai
Jia-Horng Kao
Han-Chieh Lin
Wang-Long Chuang
Chi-Yi Chen
Kuo-Chih Tseng
Chao-Hung Hung
Ming-Lung Yu
Hepatology International, 2023, 17 : 550 - 561
[22] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: THE ENDURANCE-5,6 STUDY
Asselah, Tarik
Tran, Tram T.
Alves, Katia
Nguyen, Tuan T.
Wong, Florence
Mahomed, Adam
Lim, Seng Gee
Lee, Sam
Abergel, Armando
Sasadeusz, Joe
Krishnan, Preethi
Zhang, Zhenzhen
Porcalla, Ariel R.
Trinh, Roger N.
Gane, Edward
GASTROENTEROLOGY, 2018, 154 (06) : S1190 - S1191
[23] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: THE ENDURANCE-5, 6 STUDY
Asselah, Tarik
Tram Tran
Alves, Katia
Tuan Nguyen
Wong, Florence
Mahomed, Adam
Lim, Seng Gee
Lee, Samuel S.
Abergel, Armand
Sasadeusz, Joe
Krishnan, Preethi
Zhang, Zhenzhen
Porcalla, Ariel
Trinh, Roger
Gane, Edward
GUT, 2018, 67 : A301 - A301
[24] PHARMACOKINETICS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC GENOTYPE 1-6 HEPATITIS C VIRUS INFECTION AND COMPENSATED CIRRHOSIS: AN INTEGRATED ANALYSIS
Gane, Edward
Poordad, Fred
Valdes, Joaquin M.
Lin, Chih-Wei
Liu, Wei
Asatryan, Armen
Wang, Stanley
Stedman, Catherine A.
Greenbloom, Susan
Nguyen, Tuan T.
Elkhashab, Magdy
Worns, Marcus-Alexander
Tran, Albert
Mulkay, Jean-Pierre
Yu, Yao
Porcalla, Ariel R.
Mensa, Federico
GASTROENTEROLOGY, 2017, 152 (05) : S1089 - S1089
[25] Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis
Gane, E.
Poordad, F.
Valdes, J.
Lin, C. -W.
Liu, W.
Asatryan, A.
Wang, S.
Stedman, C.
Greenbloom, S.
Nguyen, T.
Elkhashab, M.
Worns, M. -A.
Tran, A.
Mulkay, J. -P.
Yu, Y.
Porcalla, A.
Mensa, F.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S306 - S306
[26] Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with HCV Genotype 5 or 6 Infection: The ENDURANCE-5,6 Study
Asselah, T.
Tran, T.
Alves, K.
Nguyen, T.
Wong, F.
Mahomed, A.
Lim, S. G.
Lee, S.
Abergel, A.
Sasadeusz, J.
Krishnan, P.
Zhang, Z.
Pocalla, A.
Trinh, R.
Gane, E.
JOURNAL OF HEPATOLOGY, 2018, 68 : S39 - S39
[27] y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
Naganuma, Atsushi
Chayama, Kazuaki
Notsumata, Kazuo
Gane, Edward
Foster, Graham R.
Wyles, David
Kwo, Paul
Crown, Eric
Bhagat, Abhi
Mensa, Federico J.
Otani, Tetsuya
Larsen, Lois
Burroughs, Margaret
Kumada, Hiromitsu
JOURNAL OF GASTROENTEROLOGY, 2019, 54 (08) : 752 - 761
[28] Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naive, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Flamm, Steven L.
Kort, Jens
Marx, Steven E.
Strezewski, John
Dylla, Douglas E.
Bacon, Bruce
Curry, Michael P.
Tsai, Naoky
Wick, Nicole
ADVANCES IN THERAPY, 2020, 37 (05) : 2267 - 2274
[29] Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Nancy Reau
Wei-Han Cheng
Qiujun Shao
Steven E. Marx
Hannah Brooks
Anthony Martinez
Infectious Diseases and Therapy, 2023, 12 : 1849 - 1860
[30] Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis
Lampertico, Pietro
Mauss, Stefan
Persico, Marcello
Barclay, Stephen T.
Marx, Steven
Lohmann, Kristina
Bondin, Mark
Zhang, ZhenZhen
Marra, Fiona
Belperio, Pamela S.
Wedemeyer, Heiner
Flamm, Steven
ADVANCES IN THERAPY, 2020, 37 (09) : 4033 - 4042

← 1 2 3 4 5 →